Review for 10.1186/s12876-020-01484-9 (2020)

Reviewer’s report
Title: 
Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma
without distant metastasis: A cohort study
Version: 
0 
Date: 
24 Jan 2020
Reviewer's report:
The authors demonstrated the clinical significance of HER2 and Ki-67
expressions in patients with gastric cancer. There are some queries and
comments.
Comments
1) P-value should be indicated in Table 3, 4, 5, and 6.
2) In the present study, the expression status of HER2 and Ki-67 was categorized
into double negative, Ki-67 positive, HER2 positive, and double positive. How
do the authors discuss about the biological difference of each group?
3) Survival curves using Kaplan-Meier analysis in four groups should be
indicated. Then, prognostic differences should be examined using the log-rank
test.
4) In this study, the authors did not assess the prognostic significance of Ki-67.
On the other hand, the prognostic analysis for HER2 expression was done (Table
6). The prognostic analysis for Ki-67 expression should be indicated. 
5) The authors demonstrated the combined analysis of HER2 and Ki-67
expressions has the clinical utility in patients with gastric cancer. Therefore,
univariate and multivariate analyses including the combined analysis of HER2
and Ki-67 expressions should be done to assess its prognostic impact. 
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the
authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
No
Are you able to assess any statistics in the manuscript or would you
recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects
require further assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests.
I agree to the open peer review policy of the journal. I understand that my name
will be included on my report to the authors and, if the manuscript is accepted
for publication, my named report including any attachments I upload will be
posted on the website along with the authors' responses. I agree for my report to
be made available under an Open Access Creative Commons CC-BY license
(
http://creativecommons.org/licenses/by/4.0/
). I understand that any comments
which I do not wish to be included in my named report can be included as
confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal